Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza
William Blair initiated coverage on Viridian Therapeutics Inc. (NASDAQ:VRDN) on Wednesday.
Benzinga ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from Tepezza
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Topics
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
